CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novartis Pharmaceuticals Corporation v. Amneal Pharmaceuticals LLC

1:15-cv-00986

Overview

Case Number 1:15-cv-00986
Filing Date 2015-10-28
Status Terminated
Termination Date 2017-01-24
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Amneal Pharmaceuticals LLC Operating Company

Represented By

4 Attorneys Listed

Michael H. Imbacuan

Email: imbacuanm@gtlaw.com

Jennifer N. Scarpati

UNDELIVERABLE EMAIL 1/11/2017

Robert M. Vrana

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6600

Rodney Square, 1000 North King Street

Anne Shea Gaza

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6727

Rodney Square, 1000 North King Street

Plaintiff

Novartis AG Operating Company

Represented By

3 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis Pharmaceuticals Corporation Operating Company

Represented By

8 Attorneys Listed

Nathan L. Brown

UNDELIVERABALE EMAIL 8/29/2016

Katherine G. O'Brien

UNDELIVERABLE EMAIL 4/28/2016

David K. Barr

Email: david.barr@arnoldporter.com

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Daniel L. Reisner

Email: daniel.reisner@arnoldporter.com

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Abigail Langsam

Email: abigail.langsam@arnoldporter.com

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 6 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (6): 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6894051
Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Filed: 1998-07-16
Issued: 2005-05-17
Expired (Term Ended) +311d PTA
Expires: 2019-05-23
USRE43932
Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Filed: 2011-09-21
Issued: 2013-01-15
Active (4.8 yrs remaining)
Expires: 2031-09-21

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+311 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

10

Dispositive

0

Granted

0

Denied

0

Pending / Review

5

Motions by Category

Procedural / Extension Motion 9 Claim Construction / Markman Filing 1

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending
SO ORDERED, re (30 in 1:15-cv-00986-LPS, 33 in 1:15-cv-00987-LPS, 41 in 1:15-cv-00908-LPS) STIPULATION TO EXTEND TIME To allow parties additional time to confer...
Entry #— • 2016-07-14
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME To allow parties additional time to confer regarding the Proposed Protective Order to July 15, 2016 - filed by Natco Pharma Ltd.. (Bu...
Entry #30 • 2016-07-08 Document →
Claim Construction / Markman Filing Pending / Under Review
SCHEDULING ORDER: These three matters are hereby CONSOLIDATED for all purposes into C.A. No. 15-908-LPS. All papers shall be docketed in the lead case no. 15-90...
Entry #27 • 2016-05-18 Document →
Procedural / Extension Motion Pending
SO ORDERED, re (17 in 1:15-cv-00986-LPS, 18 in 1:15-cv-00987-LPS, 18 in 1:15-cv-00908-LPS) STIPULATION TO EXTEND TIME the parties to submit a Proposed Schedulin...
Entry #— • 2016-04-05
Procedural / Extension Motion Pending
SO ORDERED, re (17 in 1:15-cv-00986-LPS, 18 in 1:15-cv-00987-LPS, 18 in 1:15-cv-00908-LPS) STIPULATION TO EXTEND TIME the parties to submit a Proposed Schedulin...
Entry #— • 2016-04-05
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME the parties to submit a Proposed Scheduling Order to Monday, April 4, 2016 (from Thursday, March 31, 2016) - filed by Novartis AG, No...
Entry #17 • 2016-03-31 Document →

Docket Entries

(85 total)
Pleading / Complaint

COMPLAINT filed against Amneal Pharmaceuticals LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 1816628.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(cna) (Entered: 10/29/2015)

Entry #1 • 2015-10-28
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (cna) (Entered: 10/29/2015)

Entry #2 • 2015-10-28
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 9/8/2015. Date of Expiration of Patent: 5/23/2019; 11/23/2019; 1/16/2019; 7/16/2019.Thirty Month Stay Deadline: 3/18/2018. (cna) (Entered: 10/29/2015)

Entry #3 • 2015-10-28
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,894,051; RE43,932. (cna) (Entered: 10/29/2015)

Entry #4 • 2015-10-28
1

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Novartis AG. (cna) (Entered: 10/29/2015)

Entry #5 • 2015-10-28
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc